Cargando…
Clinical and genetic risk factors for aromatase inhibitor-associated arthralgia in breast cancer survivors
BACKGROUND: Arthralgia is a common and debilitating toxicity of aromatase inhibitors (AI) that leads to premature drug discontinuation. We sought to evaluate the clinical and genetic risk factors associated with AI-associated arthralgia (AIAA). METHODS: We performed a cross-sectional study among pos...
Autores principales: | Romero, Sally A.D., Su, H. Irene, Satagopan, Jaya, Li, Q. Susan, Seluzicki, Christina M., Dries, Annika, DeMichele, Angela M., Mao, Jun J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7375589/ https://www.ncbi.nlm.nih.gov/pubmed/31678641 http://dx.doi.org/10.1016/j.breast.2019.10.008 |
Ejemplares similares
-
Association of functional polymorphisms in CYP19A1 with aromatase inhibitor associated arthralgia in breast cancer survivors
por: Mao, Jun J, et al.
Publicado: (2011) -
Arthralgia among women taking aromatase inhibitors: is there a shared inflammatory mechanism with co-morbid fatigue and insomnia?
por: Bauml, Joshua, et al.
Publicado: (2015) -
Management of aromatase inhibitor–induced arthralgia
por: Younus, J., et al.
Publicado: (2010) -
Management of arthralgias associated with aromatase inhibitor therapy
por: Thorne, C.
Publicado: (2007) -
Joint pain severity predicts premature discontinuation of aromatase inhibitors in breast cancer survivors
por: Chim, Kannie, et al.
Publicado: (2013)